The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
In the new study, scientists at the University of Virginia used gene-editing techniques to modify GLP-1 receptors in mice to make them more humanlike
Offers a non-surgical treatment option for tricuspid regurgitation, a commonly underdiagnosed heart valve disorder linked to heart failure
The six-part webinar series aims to enhance awareness, diagnosis, and management of autoimmune diseases
The upgraded Rajajipuram centre now features enhanced retina services and advanced OCT technology
The leading cancer hospital urges carrier screening to prevent thalassemia burden
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
Subscribe To Our Newsletter & Stay Updated
